Background and Objectives:Rates of cerebrovascular disease increase after menopause which is often attributed to the absence of hormones. It remains unknown whether the cumulative exposure to hormones across a female person's premenopausal life extends the window of cerebrovascular protection to the postmenopausal period. To investigate this, we examined the relationship between lifetime hormone exposure and cerebral small vessel disease in over 9 000 postmenopausal women in the UK-Biobank.Methods:The cohort consisted of women (aged 40 to 69) that attended one of 22 research centers across the United Kingdom between 2006-2010. Women were excluded if they were premenopausal when scanned, had missing reproductive history data, self-reported neurological disorders, brain cancer, cerebral vascular incidents, head or neurological injury and nervous system infection. Endogenous lifetime hormone exposure (LHEEndo) was estimated by summing the number of years pregnant (LHEparity) with the duration of the reproductive period (LHECycle = age menopause - age menarche). Exogenous lifetime hormone exposure (LHEExo) was estimated by summing the number of years on oralcontraceptives (LHEOC) and hormone replacement therapy (LHEHRT). Cerebral small vessel disease was determined by estimating white matter hyperintensity volume (WMHV) from T2-FLAIR brain MRI (acquired between 2014 and 2021), normalized to intracranial volume and log-transformed. Multiple linear regressions were used to assess the relationship between LHEEndo on WMHV adjusted for age, cardiovascular risk factors, sociodemographics and LHEExo.Results:A total of 9163 postmenopausal women (age = 64.21 {plus minus} 6.81) were retained for analysis. Average LHEEndo was 39.77 {plus minus} 3.59 years. Women with higher LHEEndo showed smaller WMHV (R2Adj = 0.307, LHEEndo β= -0.007 (-0.012, -0.002), p <0.01). LHEparity and LHECycle were independent contributors to WMHV (R2Adj =0.308, p<<0.001; LHEparity β=-0.022, (-0.042, -0.002), p <0.05; LHECycle β=-0.006, (-0.011, -0.001), p <0.05). LHEExo was not significantly related to WMHV (LHEExo β= 0.001, (-0.001, 0.002),p>0.05).Discussion:Women with more prolonged exposure to endogenous hormones show relatively smaller burden of cerebral small vessel disease independent of history of oralcontraceptive use or hormone replacement therapy. Our results highlight the critical role endogenous hormones play in female brain health and provide real-world evidence of the protective effects premenopausalendogenous hormone exposure plays on postmenopausalcerebrovascular health.